Compare International Business Machines Corp (IBM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Sanofi SA — how do they compare? International Business Machines Corp trades at $226.67 (market cap $213.50B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: International Business Machines Corp is far larger — about 2.2× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Sanofi SA for 94 Days on average.
| IBM | SNY | |
|---|---|---|
Market Cap | $213.50B | $95.18B |
Volume | 8,908,687 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $329.23 | $52.34 |
52-Week Low | $205.77 | $39.51 |
Typical Hold Time | 88 Days | 94 Days |
Enterprise Value | $270.64B | $114.48B |
Dividend Yield | 2.98% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM stock trades at $227.13, up 3.0% today, showing resilience after recent volatility. The company reported strong Q4 2025 and Q1 2026 earnings beats but missed Q2 2026 expectations. Revenue growth accelerated to $67.54B in 2025 with net income margin improving to 15.52%. Technical indicators show bearish momentum with RSI at 71.56 suggesting overbought conditions, while analyst consensus remains positive with a $255.50 price target.
IBM's pivot to hybrid cloud and AI consulting shows promise with $5.5B generative AI bookings, though execution risks persist. The stock offers 12.5% upside to consensus target but faces headwinds from mainframe cyclicality and competitive pressure. Cash flow trends weakened in 2025 with negative net cash flow, requiring monitoring of capital allocation strategy.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
